Vyriad is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.
Investor Activity
Vyriad has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
November 14, 2019
10
64%
$38 MM
Complete list of funding rounds and total amounts in the Company Report
Trademark Applications
Trademark applications show the products and services that Vyriad is developing and marketing.
Vyriad doesn't have any recent trademark applications, indicating Vyriad is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
VYRIAD Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for providing stem cell therapy; cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use; pharmaceutical preparations for use in oncology
08/08/2023
APOLLO 19 providing medical and scientific research information in the field of clinical trials, cancer treatment, oncolytic virotherapy, pharmaceuticals, and bio-pharmaceuticals; medical scientific research, namely, analysis, testing, and development in the field of clinical trials, cancer treatment, oncolytic virotherapy, pharmaceuticals, and bio-pharmaceuticals
06/23/2020
VYRIAD APOLLO 19 providing medical and scientific research information in the field of clinical trials, cancer treatment, oncolytic virotherapy, pharmaceuticals, and bio-pharmaceuticals; medical scientific research, namely, analysis, testing, and development in the field of clinical trials, cancer treatment, oncolytic virotherapy, pharmaceuticals, and bio-pharmaceuticals
06/23/2020
See all trademarks and details in the Full Report.
Market Share of Vyriad's Largest Competitors
A competitive analysis shows these companies are in the same general field as Vyriad, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Vyriad.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Vyriad and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.
My Watch List
